Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study

Figure 2 Difference in HbA1c and fasting plasma glucose after 3 and 6 mo of treatment. A: Changes in HbA1c in the vildagliptin add-on to metformin groups and combined other oral antidiabetic drugs (OADs); B: Changes in fasting plasma glucose (FPG) in the vildagliptin add-on to metformin groups and other OADs; C: Difference in HbA1c during treatment-vildagliptin add-on to metformin, vildagliptin + metformin [single-pill combination (SPC)] and other antidiabetics (individual substance classes); D: Difference in FPG during treatment-vildagliptin add-on to metformin, vildagliptin + metformin (SPC) and other antidiabetics (individual substance classes). ¹Statistically significant difference to vildagliptin add-on to metformin at 6 mo; ²Statistically significant difference to vildagliptin + metformin (SPC) at 6 mo. IBTs: Incretin-based therapies.